Lyme disease (Borrelia burgdorferi infection) is increasingly recognized as a significant worldwide illness. This study provides insights into important immune mechanisms involved in Borrelia burgdorferi clearance in human Lyme disease.
“Whether or not” and “how” to taper off the last bit of medication for patients with clinically stable ANCA-associated vasculitis are hotly debated topics in the vasculitis field.
This study evaluates overall incidence rates and demographic, seasonal, and geographic trends of first Lyme disease diagnosis among 384,652 Maryland Medicaid members enrolled from July 2004-June 2011 and represents the first analysis of claims data from publicly insured individuals.
Patients with Post-treatment Lyme Disease Syndrome (PTLDS) commonly complain of cognitive symptoms. The study found, in subsets of PTLDS patients, objective evidence of cognitive decline in verbal memory and processing speed, cognitive impairment, and sub-optimal engagement with testing.
To our knowledge, this is the first study to explore factors which may contribute to a delay in diagnosis and treatment of Lyme disease. We identified distinct, potentially modifiable risk factors between onset of first Lyme disease symptoms and treatment. Targeting these drivers may reduce time to diagnosis and treatment and reduce the occurrence of late-stage Lyme disease complications.
This is a study of 30 patients with immune checkpoint inhibitor induced inflammatory arthritis. Their clinical features and relationship to immunotherapy regimen were evaluated, as was the course of their arthritis.
